

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/728,323
				Filing Date	December 4, 2003
				First Named Inventor	Michael J. Caplan
				Art Unit	1644
				Examiner Name	P. N. Huynh
Sheet	1	of	3	Attorney Docket Number	2006517-0010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
A1*	US-20020187158		12-12-2002	Mahler et al.	
A2*	US-20030082190		05-01-2003	Saxon et al.	
A3*	US-3,097,141		07-09-1963	Kidwell	
A4*	US-5,389,368		02-14-1995	Curtiss, III	
A5*	US-5,547,669		08-20-1996	Rogers et al.	
A6*	US-5,811,128		09-22-1998	Tice et al.	
A7*	US-5,830,463		11-03-1998	Duke et al.	
A8*	US-5,834,246		11-10-1998	Holmgren et al.	
A9*	US-5,888,799		03-30-1999	Curtiss, III	
A10*	US-6,004,815		12-21-1999	Portnoy et al.	
A11*	US-6,025,162		02-15-2000	Rogers et al.	
A12*	US-6,086,898		07-11-2000	DeKruyff et al.	
A13*	US-6,187,311		02-13-2001	Nishiyama et al.	
A14*	US-6,221,648		04-24-2001	Le Page et al.	
A15*	US-6,239,116		05-29-2001	Krieg et al.	
A16*	US-6,270,723		08-07-2001	Laugham, Jr. et al.	
A17*	US-6,486,311		11-26-2002	Burks, Jr. et al.	
A18*	US-6,506,388		01-14-2003	Shionoya et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number-Kind Code ⁴ (if known)	MM-DD-YYYY		
B1**	EP-0080806-A1		06-08-1983	Research Corp	
B2**	WO-198809669		12-15-1988	Molecular Engineering	
B3**	WO-199214487		09-03-1992	Holmgren et al	
B4**	WO-199614876		05-23-1996	The Regents of the University of Colorado	
B5**	WO-199724139		03-03-1994	Dana Farber Cancer Institute	
B6**	WO-199823763		06-04-1998	The General Hospital Corporation	
B7**	WO-199844096		10-08-1998	Cyto-Clonal Pharmaceuticals Inc.	
B8**	WO-199925387		05-27-1999	Washington University	
B9**	WO-199938978		08-05-1999	University of Arkansas et al	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.96(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IJW. *** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/728,323
				Filing Date	December 4, 2003
				First Named Inventor	Michael J. Caplan
				Art Unit	1644
				Examiner Name	P. N. Huynh
Sheet	2	of	3	Attorney Docket Number	2006517-0010

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
C1**	Aalberse et al, 2000, J Allerg Clin Immunol, 106:228-38				
C2**	Andrews et al, 1996, Gene, 182:101-9				
C3**	Blumenthal et al, 2004, Allergens and Allergen Immunotherapy, 3rd Ed, 37-50				
C4**	Burks et al, 1995, J. Clin. Invest., 96:1715-21				
C5**	Burks et al, 1997, Eur J Biochem, 245:334-39				
C6**	Burks et al, 1999, Int Arch Allerg Immunol, 118:313-14				
C7**	Chatel et al, 2003, Allergy, 58:641-47				
C8**	Chong et al, 1997, Transgenic Res, 289-296				
C9**	Colman et al, 1994, Res Immunol, 145:33-36				
C10**	Dizier et al, 1999, Gen Epidemiol, 16:305-15				
C11**	Eidelman et al, 1988, Am Rev Respir Dis, 137:1033-37				
C12**	Eko et al, 1999, Vaccine, 17:1643-49				
C13**	Evans et al, 1998, FEMS Microbiol Immunol, 47:117-25				
C14**	Fasler et al, 1998, J Aller Clin Immunol, 101:521-30				
C15**	Fenton et al, 1995, J Natl Canc Inst, 87:1853-61				
C16**	Ferreira et al, 1996, J. Exp. Med., 183:599-609				
C17**	Ferreira et al, 1998, FASEB J, 12:231-42				
C18**	Gentschev et al, 1996, Gene, 179:133-40				
C19**	Gottlieb et al, 1999, BMJ, 318:894				
C20**	Greenspan et al, 1999, Nat Biotechnol, 17:936-37				
C21**	Hansen et al, 2000, J. Immunol., 164:223-30				
C22**	Harvey et al, 1990, Remington's Pharmaceutical Sciences, 18th Ed., Chapter 35, p 711				
C23**	Hess et al, 1996, Proc Natl Acad Sci, USA, 93:1458-63				
C24**	Higgins et al, 1999, Mol Microbiol, 31:1631-41				
C25**	Hoffman et al, 1975, Immunchemistry, 12:535-38				
C26**	Ingram et al, 1980, J Bact, 144:481-88				
C27**	James et al, 1997, J Allerg Clin Immunol, 99(1):239-44 part 2				
C28**	Kieber-Janke et al, 2000, Proc Exp Purifcat, 19:419-24				
C29**	Komanapalli et al, 1998, Appl Microbiol Biotechnol, 49:766-69				
C30**	Kraft et al, 1999, Intl Arch Allerg Immunol, 118:171-76				
C31**	Lecierc et al, 1990, J Immunol, 144:3174-82				
C32**	Li et al, 2003, J. Allergy Clin. Immunol., 112(1):160-167				
C33**	Li, 1999, J. Immunol., 162:3045-52				
C34**	Mekalanos, 1992, Gen Eng Vaccines, 327:43				
C35**	Rabjohn et al, 1999, J Clin Invest, 103:535-42				
C36**	Reese et al, 2005, J Immunol, 175:8354-64				
C37**	Skolnick et al, 2000, Trend Biotech, 18:34-39				
C38**	Stanley et al, 1997, Arch Biochem Biophys, 342:244-53				
C39**	Till, 2004, Allergens and Allergen Immunotherapy, 3rd Ed, 85-104				
C40**	Vrtala et al, 1996, Int Arch Allerg Immunol, 107:290-94				
C41**	Vrtala et al, 1997, J Clin Invest, 99(7):1673-81				

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/728,323
<i>(Use as many sheets as necessary)</i>				Filing Date	December 4, 2003
Sheet	3	of	3	First Named Inventor	Michael J. Caplan
				Art Unit	1644
				Examiner Name	P. N. Huynh
				Attorney Docket Number	2006517-0010

C42**	Walker et al, 1994, Vaccine, 12:387-400	<input type="checkbox"/>
C43**	Yeung et al, 1998, J Immunol, 161:4146-52	<input type="checkbox"/>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<input type="checkbox"/>	Date Considered	
-----------------------	--------------------------	--------------------	--

4723707v1